Literature DB >> 15501004

Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).

Kazuto Okimoto1, Yuji Tokunaga, Rinta Ibuki, Tetsumi Irie, Kaneto Uekama, Roger A Rajewski, Valentino J Stella.   

Abstract

The purpose of this study was to investigate the general application of a controlled-porosity osmotic pump tablet (OPT) utilizing (SBE)7m-beta-CD as both a solubilizer and an osmotic agent for drugs with varying physical properties. OPTs utilizing (SBE)7m-beta-CD were prepared for five poorly soluble and two highly water-soluble drugs. The Japanese Pharmacopoeia dissolution method was used to study the drug and (SBE)7m-beta-CD release from the OPTs. The drug concentration in the OPT core after the OPT was placed in the release medium for two hours was assayed gravimetrically and by HPLC. An appropriate composition ratio (ACR) of (SBE)7m-beta-CD to drug at which drug release from the OPT was complete and pH-independent within the physiological pH range of the GI tract was determined for each drug. The ACR values correlate to the drug concentration in the OPT core when the OPTs were placed in the release medium for two hours. The release profiles of prednisolone (a poorly water-soluble drug) and sodium chloride (a water-soluble compound) from the OPTs were almost the same as that of (SBE)7m-beta-CD. Also, the release rate of each drug per unit membrane surface area from the OPTs was similar, regardless of the differences in drug solubility. The present results confirmed that (SBE)7m-beta-CD serves as both a solubility modulator and as an osmotic pumping agent for OPTs, from which the release rate of both water-soluble and poorly water-soluble drugs can be controlled. copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501004     DOI: 10.1016/j.ijpharm.2004.08.002

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Advanced technologies for oral controlled release: cyclodextrins for oral controlled release.

Authors:  Paulo José Salústio; Patrícia Pontes; Claúdia Conduto; Inês Sanches; Catarina Carvalho; João Arrais; Helena M Cabral Marques
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

2.  Development and optimization of micro/nanoporous osmotic pump tablets.

Authors:  Siracha Tuntikulwattana; Ampol Mitrevej; Teerakiat Kerdcharoen; Desmond B Williams; Nuttanan Sinchaipanid
Journal:  AAPS PharmSciTech       Date:  2010-05-25       Impact factor: 3.246

3.  Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets.

Authors:  Ahmed Abd-Elbary; Mina Ibrahim Tadros; Ahmed Adel Alaa-Eldin
Journal:  AAPS PharmSciTech       Date:  2011-04-09       Impact factor: 3.246

4.  Investigation of release pattern of a drug with low solubility through asymmetric membrane capsules.

Authors:  P K Sahoo; Harleen Makar
Journal:  Indian J Pharm Sci       Date:  2013-03       Impact factor: 0.975

5.  Feasibility of optimizing trimetazidine dihydrochloride release from controlled porosity osmotic pump tablets of directly compressed cores.

Authors:  Basant A Habib; Randa T Abd El Rehim; Samia A Nour
Journal:  J Adv Res       Date:  2013-06-11       Impact factor: 10.479

6.  Preparation and evaluation of bilayer-core osmotic pump tablets contained topiramate.

Authors:  Wen Lin; Yinke Li; Qiongzhi Shi; Xiangru Liao; Yuan Zeng; Wei Tian; Xiangyang Xie; Hui Liu
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.